mPGES-1 as a target for cancer suppression A comprehensive invited review "Phospholipase A2 and lipid mediators"

被引:70
作者
Nakanishi, Masako [1 ]
Gokhale, Vijay [2 ]
Meuillet, Emmanuelle J. [3 ]
Rosenberg, Daniel W. [1 ]
机构
[1] Univ Connecticut, Ctr Hlth, Ctr Mol Med, Farmington, CT 06030 USA
[2] Univ Arizona, Dept Pharm, Tucson, AZ 85721 USA
[3] Univ Arizona, Dept Nutr Sci, Tucson, AZ 85721 USA
关键词
mPGES-1; Inflammation; PGE(2); Cancer; inhibitor; PROSTAGLANDIN-E SYNTHASE-1; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PREVENT COLORECTAL ADENOMAS; E-2; SYNTHASE; PROSTANOID RECEPTORS; COLON-CANCER; INTESTINAL TUMORIGENESIS; PERITONEAL-MACROPHAGES; RHEUMATOID-ARTHRITIS; GENETIC DELETION;
D O I
10.1016/j.biochi.2010.02.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostaglandin E-2 (PGE(2)) is a bioactive lipid that can elicit a wide range of biological effects associated with inflammation and cancer. The physiological roles of PGE(2) are diverse, mediated in part through activation of key downstream signaling cascades via transmembrane EP receptors located on the cell surface. Elevated levels of COX-2 and concomitant overproduction of PGE(2) are often found in human cancers. These observations have led to the use of non-steroidal anti-inflammatory drugs (NSAIDs) as chemopreventive agents, particularly for colorectal cancer (CRC). Their long-term use, however, may be associated with gastrointestinal toxicity and increased risk of adverse cardiovascular events, prompting the development of other enzymatic targets in this pathway. This review will focus on recent efforts to target the terminal synthase, mPGES-1, for cancer chemoprevention. The role of mPGES-1 in the pathogenesis of various cancers is discussed. In addition, an overview of recent efforts to develop small molecule inhibitors that target the protein with high selectivity is also be reviewed. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:660 / 664
页数:5
相关论文
共 62 条
  • [1] ARAI I, 1993, RES COMMUN CHEM PATH, V81, P259
  • [2] A randomized trial of aspirin to prevent colorectal adenomas
    Baron, JA
    Cole, BF
    Sandler, RS
    Haile, RW
    Ahnen, D
    Bresalier, R
    McKeown-Eyssen, G
    Summers, RW
    Rothstein, R
    Burke, CA
    Snover, DC
    Church, TR
    Allen, JI
    Beach, M
    Beck, GJ
    Bond, JH
    Byers, T
    Greenberg, ER
    Mandel, JS
    Marcon, N
    Mott, LA
    Pearson, L
    Saibil, F
    van Stolk, RU
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (10) : 891 - 899
  • [3] Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial
    Baron, John A.
    Sandler, Robert S.
    Bresalier, Robert S.
    Lanas, Angel
    Morton, Dion G.
    Riddell, Robert
    Iverson, Erik R.
    DeMets, David L.
    [J]. LANCET, 2008, 372 (9651) : 1756 - 1764
  • [4] Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets
    Baryawno, Ninib
    Sveinbjornsson, Baldur
    Eksborg, Staffan
    Orrego, Abiel
    Segerstrom, Lova
    Oqvist, Carl Otto
    Holm, Stefan
    Gustavsson, Bengt
    Kagedal, Bertil
    Kogner, Per
    Johnsen, John Inge
    [J]. NEURO-ONCOLOGY, 2008, 10 (05) : 661 - 674
  • [5] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial
    Bresalier, RS
    Sandler, RS
    Quan, H
    Bolognese, JA
    Oxenius, B
    Horgan, K
    Lines, C
    Riddell, R
    Morton, D
    Lanas, A
    Konstam, MA
    Baron, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) : 1092 - 1102
  • [6] Prostanoid receptors: Subtypes and signaling
    Breyer, RM
    Bagdassarian, CK
    Myers, SA
    Breyer, MD
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 : 661 - 690
  • [7] Prostaglandin E2 pathway in head and neck squamous cell carcinoma
    Camacho, Mercedes
    Leon, Xavier
    Fernandez-Figueras, Maria-Teresa
    Quer, Miquel
    Vila, Luis
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2008, 30 (09): : 1175 - 1181
  • [8] Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-β-catenin signaling axis
    Castellone, MD
    Teramoto, H
    Williams, BO
    Druey, KM
    Gutkind, JS
    [J]. SCIENCE, 2005, 310 (5753) : 1504 - 1510
  • [9] Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function
    Cheng, Y
    Wang, M
    Yu, Y
    Lawson, J
    Funk, CD
    FitzGerald, GA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (05) : 1391 - 1399
  • [10] Celecoxib - A review of its use in osteoarthritis, rheumatoid arthritis and acute pain
    Clemett, D
    Goa, KL
    [J]. DRUGS, 2000, 59 (04) : 957 - 980